A South Florida drug maker recalled 199,584 bottles of three ophthalmic solutions because of a “lack of assurance on sterility.” ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

Stuart Therapeutics’ dry eye disease drug has failed to demonstrate that it can increase tear production in a phase 3 test.

Researchers have found in a phase 3 trial that phentolamine ophthalmic solution 0.75% led to significant improvements in ...

Global Ophthalmic Drugs Market is valued at approximately USD 38 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.10% over the forecast period 2024-2032. Read the ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

The ophthalmic solution will be available in single-dose vials with a recommended dosage of one drop in each eye twice a day. Approval of Tryptyr was based on the results of two phase 3 clinical ...

Then, on Tuesday, The U.S. Food and Drug Administration (FDA) published a report detailing the recall of bromfenac ophthalmic solution eye drops nationwide. The bottles appear to be available by ...

The Food and Drug Administration (FDA) has approved Tryptyr ® (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease.. The active ingredient in ...

Sodium Chloride Ophthalmic Solution, 5% Hypertonicity Eye Drops: 0363-0193-13; lots 19105 and 19050. Lubricant Eye Ointment PF Soothing: 0363-0191-50; lot TDB. Walmart recalled products ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin eye drop for the treatment of dry eye disease, according to a press ...